Skip to content
MedStar Georgetown University Hospital
Share this page:
The Web-based Cancer Program Practice Profile Reports (CP3R) offer local providers comparative information to assess adherence to and consideration of standard of care therapies for major cancers. This reporting tool provides a platform from which to promote continuous practice improvement to improve quality of patient care at the local level and also permits hospitals to compare their care for these patients relative to that of other providers. The aim is to empower clinicians, administrators, and other staff to work cooperatively and collaboratively to identify problems in practice and delivery and to implement best practices that will diminish disparities in care across Commission on Cancer (CoC)-accredited cancer programs.
MedStar Georgetown University Hospital CP3R Data 2016
HT - Tamoxifen or third generation aromotase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability Measure)
Comparison To: |
EPR % |
| My Cancer Program | 95 |
| My ACS Division (South Atlantic) | 93.1 |
| My Census Region (South Atlantic) | 92.3 |
| My CoC Program Type (ACAD) | 93.4 |
| My State (DC) | no data |
| All CoC Approved Programs | 93.4 |
BCSRT - Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability Measure)
Comparison To: |
EPR % |
| My Cancer Program | 97.7 |
| My ACS Division (South Atlantic) | 91.6 |
| My Census Region (South Atlantic) | 89.7 |
| My CoC Program Type (ACAD) | 90.5 |
| My State (DC) | no data |
| All CoC Approved Programs | 90.9 |
MASTRT - Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days of diagnosis) of breast cancer for women with >= 4 positive regional lymph nodes (Accountability Measure)
Comparison To: |
EPR % |
| My Cancer Program | 85.7 |
| My ACS Division (South Atlantic) | 90.1 |
| My Census Region (South Atlantic) | 87 |
| My CoC Program Type (ACAD) | 89.6 |
| My State (DC) | no data |
| All CoC Approved Programs | 89 |
12RLN - At Least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Quality Improvement Measure)
Comparison To: |
EPR % |
| My Cancer Program | 78.3 |
| My ACS Division (South Atlantic) | 92.3 |
| My Census Region (South Atlantic) | 91.6 |
| My CoC Program Type (ACAD) | 94 |
| My State (DC) | no data |
| All CoC Approved Programs | 92.7 |
RECRTCT - Preoperative chemo and radiation are administered for clinical AJCC T3N0, or Stage III; or Preoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer (Quality Improvement)
Comparison To: |
EPR % |
| My Cancer Program | 100 |
| My ACS Division (South Atlantic) | 87.8 |
| My Census Region (South Atlantic) | 86.8 |
| My CoC Program Type (ACAD) | 84.3 |
| My State (DC) | no data |
| All CoC Approved Programs | 86 |
G15RLN - At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)
Comparison To: |
EPR % |
| My Cancer Program | 71.4 |
| My ACS Division (South Atlantic) | 62.1 |
| My Census Region (South Atlantic) | 60.8 |
| My CoC Program Type (ACAD) | 71.1 |
| My State (DC) | no data |
| All CoC Approved Programs | 64.6 |
LNoSurg - Surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement)
Comparison To: |
EPR % |
| My Cancer Program | 90 |
| My ACS Division (South Atlantic) | 93.9 |
| My Census Region (South Atlantic) | 92.6 |
| My CoC Program Type (ACAD) | 92.6 |
| My State (DC) | no data |
| All CoC Approved Programs | 93.4 |
LCT - Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic lymph node-postive (pN1) and (pN2) NSCLC (Quality Improvement)
Comparison To: |
EPR % |
| My Cancer Program | 100 |
| My ACS Division (South Atlantic) | 89.9 |
| My Census Region (South Atlantic) | 88.8 |
| My CoC Program Type (ACAD) | 87.7 |
| My State (DC) | no data |
| All CoC Approved Programs | 88.6 |
nBx - Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer (Quality Improvement)
Comparison To: |
EPR % |
| My Cancer Program | 82.1 |
| My ACS Division (South Atlantic) | 90.2 |
| My Census Region (South Atlantic) | 88.9 |
| My CoC Program Type (ACAD) | 88.7 |
| My State (DC) | no data |
| All CoC Approved Programs | 89.6 |
